logo
Twitter
Discord
Email
logo
Korro Bio, Inc.

Korro Bio, Inc.

NASDAQ•KRRO
CEO: Mr. Nessan Bermingham Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2019-10-03
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Contact Information
One Kendall Square, Building 600-700 Suite 6-401, Cambridge, MA, 02139, United States
617-468-1999
www.korrobio.com
Market Cap
$101.05M
P/E (TTM)
-1.1
37
Dividend Yield
--
52W High
$55.89
52W Low
$5.20
52W Range
11%
Rank59Top 87.6%
2.2
F-Score
Modified Piotroski Analysis
Based on 8-year fundamentals
Weak • 2.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2018-2025

Financial Dashboard

Q3 2025 Data

Revenue

$1.09M+0.00%
4-Quarter Trend

EPS

-$1.92-15.04%
4-Quarter Trend

FCF

-$17.35M-17.26%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Collaboration Revenue Recognized Nine months collaboration revenue reached $5.1M, compared to zero recognized in the prior nine months period.
R&D Expenses Increased Research and development expenses rose $7.9M to $54.6M for nine months, funding pipeline advancement.
KRRO-121 Candidate Nominated Nominated KRRO-121 for UCD/HE treatment; planning first-in-human regulatory filing in second half 2026.
Cash Runway Extended Cash, cash equivalents, and marketable securities totaled $102.5M, funding operations into second half 2027.

Risk Factors

KRRO-110 Program Pivoting KRRO-110 failed to meet AATD protein goals; pivoting delivery method, which may cause development delays.
Increased Net Loss Nine months net loss widened to $67.2M from $62.4M; requires substantial future capital infusion.
Workforce Reductions Impact Implemented two workforce reductions (May and November 2025); future expansion efforts face integration challenges.
Novo Nordisk Collaboration Paused Novo Nordisk collaboration paused for 12 months starting November 2025, suspending expected revenue recognition.

Outlook

KRRO-121 Clinical Trial Filing Plan to submit regulatory filing for KRRO-121 first-in-human trial during the second half of 2026.
AATD Candidate Nomination Prioritizing GalNAc-conjugated AATD program; expect to nominate a development candidate during 2026.
Continued High R&D Spending Expect substantial increase in R&D expenses to advance pipeline through clinical development stages.
Pursuing Additional Financing Will pursue additional cash resources through public or private equity offerings, collaborations, or debt financings.

Peer Comparison

Revenue (TTM)

Amarin Corporation plcAMRN
$225.62M
-6.7%
Cellectis S.A.CLLS
$75.27M
+158.9%
ADC Therapeutics SAADCT
$75.21M
+6.4%

Gross Margin (Latest Quarter)

Korro Bio, Inc.KRRO
100.0%
+0.0pp
Cellectis S.A.CLLS
93.3%
+10.5pp
ADC Therapeutics SAADCT
92.7%
-2.7pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
RAPT$953.06M-14.7-61.8%1.6%
ENGN$623.04M-9.5-31.1%14.4%
DBVT$587.04M-3.9-295.2%0.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-21.7%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 17, 2026
|
EPS:-$1.86
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 12, 2025|
    Revenue: $1.09M+0.0%
    |
    EPS: $-1.92-15.0%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 12, 2025|
    Revenue: $1.46M+0.0%
    |
    EPS: $-2.74+12.8%
    Miss

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 7, 2025|
    Revenue: $2.55M+0.0%
    |
    EPS: $-2.49+2.0%
    Beat

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 18, 2025|
    Revenue: $2.27M+0.0%
    |
    EPS: $-9.37+82.4%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 12, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-2.26+11.3%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 13, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-2.43+25.3%
    N/A

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 14, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-2.44-31.8%
    N/A

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 26, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-53.09+76.7%
    N/A